BRIEVRE, created in 2014 (United States), from 19 sister brands and 2214 competing brands. BRIEVRE is owned by Biomarin Pharmaceutical, listed on the stock exchange of New York BRIEVRE is part of the Biotechnology activity sector.

BRIEVRE is a brand of Biomarin Pharmaceutical (BMRN) Share price

International deposit : 2014 Business sector Biotechnology

Share price and profitability of the share Biomarin Pharmaceutical (BRIEVRE)

Buy Biomarin Pharmaceutical share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested USD 82.17

Portfolio valuation
Biomarin Pharmaceutical (BRIEVRE) over 5 years* USD 79.02

Stock market history Biomarin Pharmaceutical (BRIEVRE)

*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances

Other brands
Biomarin Pharmaceutical

See more brands of Biomarin Pharmaceutical

Rival brands
BRIEVRE

NOTABLE LABS
NOTABLE LABS
Roivant
Roivant
Valerio Therapeutics
Valerio Therapeutics
INVERSAGO
INVERSAGO
Terns Pharma
Terns Pharma
Vaxcyte
Vaxcyte
OTHER RIVAL BRANDS

Top Popularity Web

See the full ranking
Desirable brands that generate Pricing Power and therefore stock market performance
Desirable brands that generate Pricing Power and therefore stock market performance

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more
MORE NEWS